Nuvation Bio Inc. (NUVB): Price and Financial Metrics
GET POWR RATINGS... FREE!
NUVB Stock Price Chart Interactive Chart >
NUVB Price/Volume Stats
| Current price | $2.42 | 52-week high | $6.23 |
| Prev. close | $2.43 | 52-week low | $1.59 |
| Day low | $2.41 | Volume | 390,225 |
| Day high | $2.55 | Avg. volume | 700,913 |
| 50-day MA | $2.00 | Dividend yield | N/A |
| 200-day MA | $2.91 | Market Cap | 528.51M |
Nuvation Bio Inc. (NUVB) Company Bio
Nuvation Bio Inc. operates as a bio-pharmaceutical company. The Company focuses on developing oncology medicines that will improve patient lives by addressing drug resistance. Nuvation Bio serves patients worldwide.
Latest NUVB News From Around the Web
Below are the latest news stories about NUVATION BIO INC that investors may wish to consider to help them evaluate NUVB as an investment opportunity.
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868NEW YORK, December 19, 2022--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced it has dosed the first patient in a Phase 1b study of its BD2-selective BET inhibitor, NUV-868, in combination with olaparib. |
Trade Alert: The Independent Director Of Nuvation Bio Inc. (NYSE:NUVB), Kathryn Falberg, Has Just Spent US$484k Buying A Few More SharesPotential Nuvation Bio Inc. ( NYSE:NUVB ) shareholders may wish to note that the Independent Director, Kathryn Falberg... |
H.C. Wainwright Sticks to Its Buy Rating for Nuvation Bio (NUVB)H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Nuvation Bio (NUVB - Research Report) today and set a price target of $4.50. The company's shares closed last Friday at $2.09.According to TipRanks, Burns is an analyst with an average return of -22.7% and a 22.60% success rate. Burns covers the Healthcare sector, focusing on stocks such as Springworks Therapeutics, MacroGenics, and BioNTech SE.Nuvation Bio has an analyst consensus of Moderate Buy, with a price target consensus of $4.50.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $10.45 and a one-year low of $1.92. Currently, Nuvation Bio has an average volume of 616.3K. |
Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business UpdateNEW YORK, November 03, 2022--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the third quarter ended September 30, 2022, and provided a business update. |
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer FoxMaraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announce |
NUVB Price Returns
| 1-mo | 38.29% |
| 3-mo | 9.01% |
| 6-mo | -12.32% |
| 1-year | -57.24% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 26.04% |
| 2022 | -77.41% |
| 2021 | -27.35% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...